Effect of platelet activation on coronary collateral blood flow.
BACKGROUND
The platelet products thromboxane A2 and serotonin have been shown to cause constriction of well-developed coronary collateral vessels. This study was performed to determine whether intravascular platelet activation produced with platelet activating factor (PAF) can cause a decrease in coronary collateral blood flow.


RESULTS
Collateral vessel growth was induced by embolization of a hollow stainless steel plug into the left anterior descending coronary artery (LAD) of adult dogs. The animals were returned to the laboratory 3 to 6 weeks later for surgical instrumentation and measurement of collateral blood flow. Collateral flow was assessed by measuring retrograde blood flow from the cannulated collateral-dependent artery. PAF (10 nmol) was injected into the left main coronary artery to allow products of platelet activation to reach collateral vessels arising from the left coronary system. PAF caused a vasoconstrictor response, which became maximal 3 minutes after injection and resulted in a 40.3+/-7.4% decrease in retrograde blood flow (32.1+/-2.1 to 19.6+/-3.2 mL/min; P<0.05). By 15 minutes after the PAF injection, both retrograde blood flow and transcollateral resistance had returned to normal. After pretreatment with the thromboxane A2 receptor antagonist SQ30, 741, the vasoconstrictor response to PAF was abolished and, in contrast to the decrease in retrograde blood flow from PAF alone, a weak vasodilator effect was unmasked.


CONCLUSIONS
PAF caused a decrease in coronary collateral blood flow. This vasoconstrictor response required the participation of thromboxane A2.
Division of Cardiology, Department of Internal Medicine, University of Minnesota Medical School, Minneapolis, Minn, USA.
J W
JW
Kinn
R J
RJ
Bache
D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D003097:Collateral Circulation; D003326:Coronary Circulation; D004285:Dogs; D017202:Myocardial Ischemia / Q000150:complications / Q000378:metabolism; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D015539:Platelet Activation / Q000187:drug effects; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology
C029271:O-deacetyl platelet activating factor; D010972:Platelet Activating Factor; C054215:SQ 30741; D013928:Thromboxane A2